fluorouracil has been researched along with Fecal Incontinence in 14 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Fecal Incontinence: Failure of voluntary control of the anal sphincters, with involuntary passage of feces and flatus.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fecal incontinence was high after sphincter preservation." | 3.11 | Quality of life in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer-INCAGI004. ( Araujo, RO; Ferreira, CG; Guaraldi, S; Linhares, E; Martins, I; Thuler, LC; Torres, C; Valadão, M; Victorino, AP; Vieira, FM, 2022) |
| "Consecutive patients with distal rectal cancer undergoing neoadjuvant chemoradiation (50." | 2.82 | Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation. ( Fernandez, LM; Gama-Rodrigues, J; Habr-Gama, A; Jorge, JM; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2016) |
| "Patients (N = 207) with nonresectable rectal cancer were randomized to preoperative CRT or RT (2 Gy × 25 ± 5-fluorouracil/leucovorin)." | 2.76 | Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. ( Berglund, Å; Bruheim, K; Brændengen, M; Cvancarova, M; Glimelius, B; Tveit, KM, 2011) |
| "Celecoxib dosage was fixed." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| " CPT-11 (50 mg/m(2) weekly) and 5-FU (225 mg/m(2)/day continuous infusion, 5 days/week) were concurrently administered with radiation therapy (RT) (45 Gy, 1." | 2.72 | A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. ( Aranda, E; Cervantes, A; Dotor, E; Gallén, M; García, JL; Navarro, M; Rivera, F; Sánchez-Rovira, P; Vega-Villegas, ME, 2006) |
| "Treatment of rectal cancer over the last two decades has evolved with changes in techniques of surgery and radiation based on national and international trials." | 2.44 | Total mesorectal excision and management of rectal cancer. ( Phang, PT; Pinsk, I, 2007) |
| "Fecal incontinence was assessed by patient self-reported data without the use of a validated score." | 1.39 | Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer. ( Buchner, S; Dinnewitzer, A; Jäger, T; Nawara, C; Öfner, D; Wolfgang, H, 2013) |
| "Intersphincteric resection of low rectal tumors is a surgical technique extending rectal resection into the intersphincteric space." | 1.33 | Technique and long-term results of intersphincteric resection for low rectal cancer. ( Feil, W; Hölbling, N; Holzer, B; Novi, G; Renner, K; Rosen, HR; Schiessel, R; Urban, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Araujo, RO | 1 |
| Vieira, FM | 1 |
| Victorino, AP | 1 |
| Torres, C | 1 |
| Martins, I | 1 |
| Guaraldi, S | 1 |
| Valadão, M | 1 |
| Linhares, E | 1 |
| Ferreira, CG | 1 |
| Thuler, LC | 1 |
| Dinnewitzer, A | 1 |
| Jäger, T | 1 |
| Nawara, C | 1 |
| Buchner, S | 1 |
| Wolfgang, H | 1 |
| Öfner, D | 1 |
| Ihn, MH | 1 |
| Kang, SB | 1 |
| Kim, DW | 1 |
| Oh, HK | 1 |
| Lee, SY | 1 |
| Hong, SM | 1 |
| Habr-Gama, A | 1 |
| Lynn, PB | 1 |
| Jorge, JM | 1 |
| São Julião, GP | 1 |
| Proscurshim, I | 1 |
| Gama-Rodrigues, J | 1 |
| Fernandez, LM | 1 |
| Perez, RO | 1 |
| Joseph, K | 1 |
| Vos, LJ | 1 |
| Warkentin, H | 1 |
| Paulson, K | 1 |
| Polkosnik, LA | 1 |
| Usmani, N | 1 |
| Tankel, K | 1 |
| Severin, D | 1 |
| Nijjar, T | 1 |
| Schiller, D | 1 |
| Wong, C | 1 |
| Ghosh, S | 1 |
| Mulder, K | 1 |
| Field, C | 1 |
| Canda, AE | 1 |
| Terzi, C | 1 |
| Gorken, IB | 1 |
| Oztop, I | 1 |
| Sokmen, S | 1 |
| Fuzun, M | 1 |
| Malik, I | 1 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Garberoglio, C | 1 |
| Brændengen, M | 1 |
| Tveit, KM | 1 |
| Bruheim, K | 1 |
| Cvancarova, M | 1 |
| Berglund, Å | 1 |
| Glimelius, B | 1 |
| Schiessel, R | 1 |
| Novi, G | 1 |
| Holzer, B | 1 |
| Rosen, HR | 1 |
| Renner, K | 1 |
| Hölbling, N | 1 |
| Feil, W | 1 |
| Urban, M | 1 |
| Theisen, J | 1 |
| Kauer, WK | 1 |
| Nekarda, H | 1 |
| Schmid, L | 1 |
| Stein, HJ | 1 |
| Siewert, JR | 1 |
| Navarro, M | 1 |
| Dotor, E | 1 |
| Rivera, F | 1 |
| Sánchez-Rovira, P | 1 |
| Vega-Villegas, ME | 1 |
| Cervantes, A | 1 |
| García, JL | 1 |
| Gallén, M | 1 |
| Aranda, E | 1 |
| Urso, E | 1 |
| Serpentini, S | 1 |
| Pucciarelli, S | 1 |
| De Salvo, GL | 1 |
| Friso, ML | 1 |
| Fabris, G | 1 |
| Lonardi, S | 1 |
| Ferraro, B | 1 |
| Bruttocao, A | 1 |
| Aschele, C | 1 |
| Nitti, D | 1 |
| Pinsk, I | 1 |
| Phang, PT | 1 |
| Vordermark, D | 1 |
| Flentje, M | 1 |
| Sailer, M | 1 |
| Kölbl, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2011-01-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluorouracil and Fecal Incontinence
| Article | Year |
|---|---|
Total mesorectal excision and management of rectal cancer.
Topics: Adenocarcinoma; Anastomosis, Surgical; Antineoplastic Agents; Combined Modality Therapy; Disease Man | 2007 |
8 trials available for fluorouracil and Fecal Incontinence
| Article | Year |
|---|---|
Quality of life in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer-INCAGI004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fecal Incontinence; | 2022 |
Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
Topics: Adenocarcinoma; Aged; Anal Canal; Antimetabolites, Antineoplastic; Chemoradiotherapy; Fecal Incontin | 2016 |
Patient reported quality of life after helical IMRT based concurrent chemoradiation of locally advanced anal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc | 2016 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Diagnostic | 2011 |
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy | 2006 |
Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachythera | 2001 |
5 other studies available for fluorouracil and Fecal Incontinence
| Article | Year |
|---|---|
Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Anastomosis, Surgical; Anastomotic Leak; | 2013 |
Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2010 |
Technique and long-term results of intersphincteric resection for low rectal cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Neoadjuvant radiochemotherapy for patients with locally advanced rectal cancer leads to impairment of the anal sphincter.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2006 |